Nicotine abstinence syndrome precipitated by central but not peripheral hexamethonium

Pharmacology Biochemistry and Behavior

Volumn 58, Issue 3, 1997, Pages 695-699

  Malin, David H ^a   Lake, J Ronald ^a   Schopen, Christina K ^a   Kirk, John W ^a   Sailer, Elizabeth E ^a   Lawless, Brent A ^a   Upchurch, Timothy P ^a   Shenoi, Merle ^a   Rajan, Nancy ^a  

^a UNIVERSITY OF HOUSTON CLEAR LAKE   (United States)

Author keywords

Hexamethonium; Nicotine; Nicotine abstinence; Nicotine dependence; Nicotinic receptor antagonists

Indexed keywords

HEXAMETHONIUM; MECAMYLAMINE; NICOTINE; NICOTINE TARTRATE; NICOTINIC RECEPTOR BLOCKING AGENT;

ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG DEPENDENCE; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; WITHDRAWAL SYNDROME;

EID: 0030866692     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(97)90006-X     Document Type: Article

References (53)

1. Armitage A. K., Hall G. H. Effects of nicotine on the systemic blood pressure when injected into the cerebral ventricles of cats. Int. J. Neuropharmacol. 6:1967;143-149.
2. Ascher P., Large W. A., Rang H. P. Studies on the mechanism of action of acetylcholine antagonists on rat parasympathetic ganglion cells. J. Physiol. 295:1979;139-170.
3. Asghar K., Roth L. J. Entry and distribution of hexamethonium in the central nervous system. Biochem. Pharmacol. 20:1971;2787-2795.
4. Benwell M. E., Balfour D. J., Birrell C. E. Desensitization of the nicotine-induced mesolimbic dopamine responses during constant infusion with nicotine. Br. J. Pharmacol. 114:1995;454-460.
5. Bertrand D., Ballivet M., Rungger D. Activation and blocking of neuronal nicotinic acetylcholine receptors reconstituted in Xenopus oocytes. Proc. Natl. Acad. Sci. USA. 87:1990;1993-1997.
6. Blackman J. G. Dependence on membrane potential of the blocking action of hexamethonium at a sympathetic ganglionic synapse. Proc. Univ. Otago Med. Sch. 48:1970;4-5.
7. Brazell M. P., Mitchell S. N., Gray J. A. Effect of acute adminstration of nicotine on in vivo release of noradrenaline in the hippocampus of freely moving rats. A dose response and antagonist study Neuropharmacology. 30:1991;823-833.
8. Corrigall W. A., Coen K. M. Nicotine maintains robust self- administration in rats on a limited-access schedule. Psychopharmacology. 99:1989;473-478.
9. Damaj M. I., Martin B. R. Calcium agonists and antagonists of the dihydropyridine type. Effect on nicotine induced antinociception and hypomotility Drug Alcohol Depend. 32:1993;73-79.
10. Davenport K. E., Houdi A. A., Van Loon G. R. Nicotine protects against mu opioid receptor antagonism by beta-funaltrexamine. Evidence for nicotine induced release of endogenous opioid Neurosci. Lett. 113:1990;40-46.
11. Day M. D. Autonomic pharmacology. Experimental and clinical aspects:1979;Churchill Livingston, New York.
12. Endoh K., Kao J., Baker M., Leung F. W. Intragastric nicotine protection against 40% ethanol injury in rat stomach. Role of ganglionic stimulation or blockade Dig. Dis. Sci. 37:1992;1840-1846.
13. Feldberg W., Guertzenstein P. G. Vasodepressor effects obtained by drugs acting on the ventral surface of the brain stem. J. Physiol. 258:1976;337-355.
14. Gilbert D. G., Meliska C. J., Williams C. L., Jensen R. A. Subjective correlates of cigarette-smoking-induced elevations of peripheral beta-endorphin and cortisol. Psychopharmacology. 106:1992;275-281.
15. Gomita Y., Suemaru K., Furuno K., Araki Y. Nicotine- induced tail-tremor and drug effects. Pharmacol. Biochem. Behav. 34:1988;817-821.
16. Gosling J. A., Lu T. C. Uptake and distribution of some quaternery ammonium compounds in the central nervous system of the rat. J. Pharmacol. Exper. Ther. 167:1969;56-62.
17. Hall G. H. Changes in body temperature produced by cholinomimetic substances injected into the cerebral ventricle of unanesthetized cats. Br. J. Pharmacol. 44:1972;634-641.
18. Hall G. H., Reit E. Analysis of some central actions of nicotine injected into the cerebral ventricles of cats. J. Physiol. 185:1966;400-417.
19. Hexum T. D., Rossett L. R. Plasma enkephalin-like peptide response to chronic nicotine infusion in guinea pig. Brain Res. 406:1987;370-372.
20. Hildebrand B. E., Nomikos G. G., Bondjers C., Nisell M., Krahl S. E., Svensson T. H. Behavioral manifestations of the nicotine abstinence syndrome in the rat. Soc. Neurosci. Abstr. 21:1995;1471.
21. Houdi A. A., Dowell R. T., Diana J. N. Cardiovascular responses to cigarette smoke exposure in restrained conscious rats. J. Pharmacol. Exp. Ther. 275:1995;646-653.
22. Jensen R. A., Gilbert D. G., Meliska C. J., Landrom T. A. Characterization of a dose response curve for nicotine induced conditioned taste aversion in rats. Relationship to elevation of plasma β-endorphin concentration Behav. Neural Biol. 53:1990;428-440.
23. Khan I., Taylor P., Yaksh T. Cardiovascular and behavioral responses to nicotinic agents administered intrathecally. J. Pharmacol. Exp. Ther. 270:1994;150-158.
24. Koob G. F., Maldonado R., Stinus L. Neural substrates of opiate withdrawal. Trends Neurosci. 15:1992;186-191.
25. 3H]acetylcholine to nicotinic receptors. Neuropharmacology. 24:1985;527-531.
26. Levin E. D., Ellison G. D., Salem C., Jarvik M., Gritz E. Behavioral effects of acute hexamethonium in rats chronically intoxicated with nicotine. Physiol. Behav. 44:1988;355-359.
27. Levine R. R. Presence of certain onium compounds in brain tissue following intravenous administration in rats. Nature. 184:1959;1413-1414.
28. 3H](-)nicotine binding in rat cortex. Neuropharmacology. 32:1993;847-853.
29. Malin D. H., Lake J. R., Carter V. A., Cunningham J. S., Hebert K. M., Conrad D. L., Wilson O. B. The nicotinic antagonist mecamylamine precipitates nicotine abstinence syndrome in the rat. Psychopharmacology. 115:1994;180-184.
30. Malin D. H., Lake J. R., Carter V. A., Cunningham J. S., Wilson O. B. Naloxone precipitates nicotine abstinence syndrome in the rat. Psychopharmacology. 112:1993;339-342.
31. 2-like mammalian peptide precipitates opiate withdrawal syndrome in the rat. Peptides. 11:1990;277-280.
32. 2-like mammalian octapeptide in opiate dependence and withdrawal. Harris L. Problems of drug dependence 1990. Proceedings of the 52nd annual scientific meeting:1991;271-277 NIDA, Rockville, MD.
33. Malin D. H., Lake J. R., Leyva J. E., Hammond M. V., Rogillio R. B., Arcangeli K. R., Ludgate K., Moore G. M., Payza K. Analog of neuropeptide FF attenuates morphine abstinence syndrome. Peptides. 12:1991;1011-1014.
34. Malin D. H., Lake J. R., Newlin-Maultsby P., Roberts L. K., Lanier J. G., Carter V. A., Cunningham J. S., Wilson O. B. A rodent model of nicotine abstinence syndrome. Pharmacol. Biochem. Behav. 43:1992;779-784.
35. Malin D. H., Lake J. R., Payne M. C., Short P. E., Carter V. A., Cunningham J. S., Wilson O. B. Nicotine alleviation of nicotine abstinence syndrome is naloxone-reversible. Pharmacol. Biochem. Behav. 53:1996;81-85.
36. Malin D. H., Lake J. R., Short P. E., Blossman J. B., Lawless B. A., Schopen C. K., Sailer E. E., Burgess K., Wilson O. B. Nicotine abstinence syndrome precipitated by an analog of neuropeptide FF. Pharmacol. Biochem. Behav. 54:1996;581-585.
37. Malin D. H., Murray J. B., Crucian G. P., Schweitzer F. C., Cook R. E., Skolnick M. H. Auricular microelectrostimulation. Naloxone reversible attenuation of opiate abstinence syndrome Biol. Psychiatr. 24:1988;886-890.
38. Martin B. R., Martin T. J., Fan F., Damaj M. I. Central actions of nicotine antagonists. Med. Chem. Res. 2:1993;564-577.
39. Martin B. R., Onaivi E. S., Martin T. J. What is the nature of mecamylamine's antagonism of the central effects of nicotine? Biochem. Pharmacol. 38:1989;3391-3397.
40. Matta S. G., Beyer H. S., McAllen K. M., Sharp B. M. Nicotine elevates rat plasma ACTH by central mechanism. J. Pharmacol Exp. Ther. 243:1987;217-226.
41. Meltzer L. T., Rosecrans J. A. Nicotine and arecoline as discriminative stimuli. Involvement of a non-cholinergic mechanism for nicotine Pharmacol. Biochem. Behav. 29:1988;587-593.
42. O'Dell T. J., Christensen B. N. Mecamylamine is a selective noncompetitive antagonist of NMDA and ASP-induced currents in horizontal cells dissociated from the catfish retina. Neurosci. Lett. 94:1988;93-98.
43. Okamoto M., Kita T., Okuda H., Nakashima T. Tolerance to the convulsions induced by daily nicotine treatment in rats. Jap. J. Pharmacol. 59:1992;449-455.
44. Pomerleau O. F., Fertig J. B., Seyler E., Jaffe J. Neuroendocrine reactivity to nicotine in smokers. Psychopharmacology. 81:1983;61-67.
45. Ren T., Sagar S. M. Induction of c-fos immunostaining in the rat brain after the systemic administration of nicotine. Brain Res. Bull. 29:1992;589-597.
46. Rosecrans J. A., Hendry J. S., Hong J. S. Biphasic effects of chronic nicotine treatment on hypothalamic immunoreactive beta- endorphin in the mouse. Pharmacol. Biochem. Behav. 23:1985;141-143.
47. Schechter M. D., Cook P. G. Nicotine-induced weight loss in rats without an effect on appetite. Eur. J. Pharmacol. 38:1976;63-69.
48. Sharp B., Matta S. Detection by in vivo micro-dialysis of nicotine-induced norepinephrine secretion from the hypothalamic paraventricular nucleus of freely moving rats. dose dependency and desensitization Endocrinol. 133:1993;11-19.
49. Suemaru K., Oishi R., Gomita Y. Characteristics of tail-tremor induced by nicotine in rats. Naunyn-Schmiedebergs Arch. Pharmacol. 350:1994;153-157.
50. Suh H. W., Hudson P. M., McMillian M. K., Das K. P., Wilson B. C., Wu G. C., Hong J. S. Long-term stimulation of nicotinic receptors is required to increase proenkephalin A mRNA levels and the delayed secretion of [Met5]-enkephalin in bovine adrenal medullary chromaffin cells. J. Pharmacol. Exp. Ther. 275:1995;1663-1670.
51. Takayama H., Majewska M. D., London E. D. Interactions of noncompetitive inhibitors with nicotinic receptors in the rat brain. J. Pharmacol. Exp. Ther. 253:1989;1083-1089.
52. Varanda W. A., Aracava Y., Sherby S. M., Van Meter W. G., Eldefrawi M. E., Albuquerque E. X. The ACh receptor of the neuromuscular junction recognizes mecamylamine as a noncompetitive antagonist. Mol. Pharmacol. 28:1985;128-137.
53. Yamada S., Kagawa Y., Takayanagi N., Nakayama K., Tsuji K., Kosuge T., Hayashi E., Okada K., Inoue S. Comparison of antinicotinic activity by neosurugatoxin and the structurally related compounds. J. Pharmacol. Exp. Ther. 243:1987;1153-1158.